Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry

Hong Hee Lee, Areum Hong, Yunju Cho, Sunghwan Kim, Won Jong Kim, Hugh I. Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Paclitaxel (PTX) is a popular anticancer drug used in the treatment of various types of cancers. PTX is metabolized in the human liver by cytochrome P450 to two structural isomers, 3′-p-hydroxypaclitaxel (3p-OHP) and 6α-hydroxypaclitaxel (6α-OHP). Analyzing PTX and its two metabolites, 3p-OHP and 6α-OHP, is crucial for understanding general pharmacokinetics, drug activity, and drug resistance. In this study, electrospray ionization ion mobility mass spectrometry (ESI-IM-MS) and collision induced dissociation (CID) are utilized for the identification and characterization of PTX and its metabolites. Ion mobility distributions of 3p-OHP and 6α-OHP indicate that hydroxylation of PTX at different sites yields distinct gas phase structures. Addition of monovalent alkali metal and silver metal cations enhances the distinct dissociation patterns of these structural isomers. The differences observed in the CID patterns of metalated PTX and its two metabolites are investigated further by evaluating their gas-phase structures. Density functional theory calculations suggest that the observed structural changes and dissociation pathways are the result of the interactions between the metal cation and the hydroxyl substituents in PTX metabolites. [Figure not available: see fulltext.]

Original languageEnglish
Pages (from-to)329-338
Number of pages10
JournalJournal of the American Society for Mass Spectrometry
Volume27
Issue number2
DOIs
Publication statusPublished - 2016 Feb 1

Fingerprint

Metabolites
Tandem Mass Spectrometry
Paclitaxel
Mass spectrometry
Ions
Pharmaceutical Preparations
Phase structure
Isomers
Cations
Gases
Metals
Alkali Metals
Electrospray ionization
Hydroxylation
Pharmacokinetics
Silver
Drug Resistance
Hydroxyl Radical
Liver
Cytochrome P-450 Enzyme System

Keywords

  • 3′-p-Hydroxypaclitaxel
  • 6α-Hydroxypaclitaxel
  • Alkali metal
  • Collision induced dissociation
  • Density functional theory
  • Fragmentation pathway
  • Ion mobility mass spectrometry
  • Metabolites
  • Paclitaxel
  • Silver
  • Structural characterization

ASJC Scopus subject areas

  • Structural Biology
  • Spectroscopy

Cite this

Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry. / Lee, Hong Hee; Hong, Areum; Cho, Yunju; Kim, Sunghwan; Kim, Won Jong; Kim, Hugh I.

In: Journal of the American Society for Mass Spectrometry, Vol. 27, No. 2, 01.02.2016, p. 329-338.

Research output: Contribution to journalArticle

@article{94e76930b39a4b9095c9459aa42573f0,
title = "Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry",
abstract = "Paclitaxel (PTX) is a popular anticancer drug used in the treatment of various types of cancers. PTX is metabolized in the human liver by cytochrome P450 to two structural isomers, 3′-p-hydroxypaclitaxel (3p-OHP) and 6α-hydroxypaclitaxel (6α-OHP). Analyzing PTX and its two metabolites, 3p-OHP and 6α-OHP, is crucial for understanding general pharmacokinetics, drug activity, and drug resistance. In this study, electrospray ionization ion mobility mass spectrometry (ESI-IM-MS) and collision induced dissociation (CID) are utilized for the identification and characterization of PTX and its metabolites. Ion mobility distributions of 3p-OHP and 6α-OHP indicate that hydroxylation of PTX at different sites yields distinct gas phase structures. Addition of monovalent alkali metal and silver metal cations enhances the distinct dissociation patterns of these structural isomers. The differences observed in the CID patterns of metalated PTX and its two metabolites are investigated further by evaluating their gas-phase structures. Density functional theory calculations suggest that the observed structural changes and dissociation pathways are the result of the interactions between the metal cation and the hydroxyl substituents in PTX metabolites. [Figure not available: see fulltext.]",
keywords = "3′-p-Hydroxypaclitaxel, 6α-Hydroxypaclitaxel, Alkali metal, Collision induced dissociation, Density functional theory, Fragmentation pathway, Ion mobility mass spectrometry, Metabolites, Paclitaxel, Silver, Structural characterization",
author = "Lee, {Hong Hee} and Areum Hong and Yunju Cho and Sunghwan Kim and Kim, {Won Jong} and Kim, {Hugh I.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s13361-015-1280-1",
language = "English",
volume = "27",
pages = "329--338",
journal = "Journal of the American Society for Mass Spectrometry",
issn = "1044-0305",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Structural Characterization of Anticancer Drug Paclitaxel and Its Metabolites Using Ion Mobility Mass Spectrometry and Tandem Mass Spectrometry

AU - Lee, Hong Hee

AU - Hong, Areum

AU - Cho, Yunju

AU - Kim, Sunghwan

AU - Kim, Won Jong

AU - Kim, Hugh I.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Paclitaxel (PTX) is a popular anticancer drug used in the treatment of various types of cancers. PTX is metabolized in the human liver by cytochrome P450 to two structural isomers, 3′-p-hydroxypaclitaxel (3p-OHP) and 6α-hydroxypaclitaxel (6α-OHP). Analyzing PTX and its two metabolites, 3p-OHP and 6α-OHP, is crucial for understanding general pharmacokinetics, drug activity, and drug resistance. In this study, electrospray ionization ion mobility mass spectrometry (ESI-IM-MS) and collision induced dissociation (CID) are utilized for the identification and characterization of PTX and its metabolites. Ion mobility distributions of 3p-OHP and 6α-OHP indicate that hydroxylation of PTX at different sites yields distinct gas phase structures. Addition of monovalent alkali metal and silver metal cations enhances the distinct dissociation patterns of these structural isomers. The differences observed in the CID patterns of metalated PTX and its two metabolites are investigated further by evaluating their gas-phase structures. Density functional theory calculations suggest that the observed structural changes and dissociation pathways are the result of the interactions between the metal cation and the hydroxyl substituents in PTX metabolites. [Figure not available: see fulltext.]

AB - Paclitaxel (PTX) is a popular anticancer drug used in the treatment of various types of cancers. PTX is metabolized in the human liver by cytochrome P450 to two structural isomers, 3′-p-hydroxypaclitaxel (3p-OHP) and 6α-hydroxypaclitaxel (6α-OHP). Analyzing PTX and its two metabolites, 3p-OHP and 6α-OHP, is crucial for understanding general pharmacokinetics, drug activity, and drug resistance. In this study, electrospray ionization ion mobility mass spectrometry (ESI-IM-MS) and collision induced dissociation (CID) are utilized for the identification and characterization of PTX and its metabolites. Ion mobility distributions of 3p-OHP and 6α-OHP indicate that hydroxylation of PTX at different sites yields distinct gas phase structures. Addition of monovalent alkali metal and silver metal cations enhances the distinct dissociation patterns of these structural isomers. The differences observed in the CID patterns of metalated PTX and its two metabolites are investigated further by evaluating their gas-phase structures. Density functional theory calculations suggest that the observed structural changes and dissociation pathways are the result of the interactions between the metal cation and the hydroxyl substituents in PTX metabolites. [Figure not available: see fulltext.]

KW - 3′-p-Hydroxypaclitaxel

KW - 6α-Hydroxypaclitaxel

KW - Alkali metal

KW - Collision induced dissociation

KW - Density functional theory

KW - Fragmentation pathway

KW - Ion mobility mass spectrometry

KW - Metabolites

KW - Paclitaxel

KW - Silver

KW - Structural characterization

UR - http://www.scopus.com/inward/record.url?scp=84955479403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955479403&partnerID=8YFLogxK

U2 - 10.1007/s13361-015-1280-1

DO - 10.1007/s13361-015-1280-1

M3 - Article

VL - 27

SP - 329

EP - 338

JO - Journal of the American Society for Mass Spectrometry

JF - Journal of the American Society for Mass Spectrometry

SN - 1044-0305

IS - 2

ER -